Rezolute
Developing ersodetug for hypoglycemia caused by congenital and tumor hyperinsulinism.
$4.65
After-hours close+0.03 (+0.65%)
At close$4.62(−7.23%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 89.64%Insiders 10.70%
Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.
Shares outstanding 96.29M · Float 66.01M · 68.6% free float
Institutions13F, as of Mar 31, 2026
132 holders · 86.32M shares · 34 new positions · 73 increased · 39 reduced · 38 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Federated Hermes, Inc. | 12.99M | 13.49% | −3.54M | May 11, 2026 |
| Ra Capital Management, L.P. | 9.18M | 9.53% | 0 | May 15, 2026 |
| BlackRock, Inc. | 6.31M | 6.56% | −454.7K | May 13, 2026 |
| Opaleye Management Inc. | 6.30M | 6.54% | +12.8K | May 15, 2026 |
| Balyasny Asset Management L.P. | 5.05M | 5.24% | +541.6K | May 15, 2026 |
| Vanguard Capital Management LLC | 3.52M | 3.66% | +3.52Mnew | May 15, 2026 |
| Jennison Associates LLC | 3.44M | 3.57% | +3.44Mnew | May 6, 2026 |
| Siren, L.L.C. | 3.33M | 3.46% | +3.33M | May 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| RA Capital Management, L.P. | 9.90% | 9.18M | 13G | Dec 18, 2025 ↗ |
| Opaleye Management Inc. | 6.58% | 6.30M | 13G | May 11, 2026 ↗ |
| Bank of America Corp /DE/ | 6.50% | 6.06M | 13G | Feb 11, 2026 ↗ |
| BlackRock, Inc. | 5.40% | 4.88M | 13G | Oct 17, 2025 ↗ |
| Balyasny Asset Management L.P. | 5.28% | 5.05M | 13G | May 15, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Young-Jin Kim | director | 8.59M | 8.93% | Nov 21, 2025 |
| Nevan C. Elam | director, officer: CEO | 605.5K | 0.63% | Jul 7, 2026 |
| Daron Evans | officer: CFO | 418.4K | 0.43% | Jul 7, 2026 |
| Brian Kenneth Roberts | officer: Chief Medical Officer | 293.9K | 0.31% | Jul 7, 2026 |
| Wladimir Hogenhuis | director | 119.7K | 0.12% | Dec 17, 2025 |
| Sunil Ratilal Karnawat | officer: Chief Commercial Officer | 79.4K | 0.08% | Dec 15, 2025 |
| Nerissa Kreher | director | 58.6K | 0.06% | Nov 21, 2025 |
| Philippe Fauchet | director | 55.5K | 0.06% | Nov 21, 2025 |
| Gil M. Labrucherie | director | 55.5K | 0.06% | Nov 21, 2025 |
| Erik Harris | director | 21.0K | 0.02% | Nov 21, 2025 |
5 ten-percent owners hold 91.50M shares by Form 4, outside the officers-and-directors figure above · 5 people have not refiled in the last 18 months (6.02M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Mar 30, 2026 | Daron Evansofficer: CFO | Purchase | 10,000 | $2.85 | 414,462 |
| Dec 16, 2025 | Brian Kenneth Robertsofficer: Chief Medical Officer | Purchase | 28,000 | $1.70 | 308,352 |
| Dec 16, 2025 | Wladimir Hogenhuisdirector | Purchase | 5,650 | $1.69 | 119,675 |
| Dec 15, 2025 | Sunil Ratilal Karnawatofficer: Chief Commercial Officer | Purchase · 2 lots | 12,100 | $1.62 | 71,542 |
| Dec 15, 2025 | Nevan C. Elamdirector, officer: CEO | Purchase | 32,000 | $1.59 | 641,119 |
| Dec 15, 2025 | Daron Evansofficer: CFO | Purchase · 3 lots | 45,000 | $1.77 | 422,900 |
CongressHouse and Senate disclosures
Not reported.